

# The influence of O/S exchange on the biocatalytical activity of benzoselenazol-3(2H)-ones

M. Obieziurska<sup>a</sup>, A. J. Pacuła<sup>a</sup>, U. Juhas<sup>b,c</sup>, J. Antosiewicz<sup>b</sup> and J. Ścianowski<sup>a\*</sup>

<sup>a</sup>Department of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarin Street, 87-100 Torun, Poland

<sup>b</sup>Department of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, 1 Debinki Street, 80-211 Gdansk, Poland

<sup>c</sup>Department of Immunology, Medical University of Gdansk, 1 Debinki Street, 80-211 Gdansk, Poland


\*E-mail: [jsch@chem.umk.pl](mailto:jsch@chem.umk.pl)

## Supporting Information: NMR spectra


### Index of content:

|      |                                                                                                                                   |    |
|------|-----------------------------------------------------------------------------------------------------------------------------------|----|
| I.   | <sup>1</sup> H and <sup>13</sup> C NMR spectra of <i>o</i> -iodobenzamides <b>4a</b> , <b>4b</b> and <b>4d</b>                    | 2  |
| II.  | <sup>1</sup> H and <sup>13</sup> C NMR spectra of <i>o</i> -iodothiobenzamides <b>5a-5f</b>                                       | 8  |
| III. | <sup>1</sup> H, <sup>13</sup> C and <sup>77</sup> Se NMR spectra of benzoselenazol-3(2H)-ones <b>6a</b> , <b>6b</b> and <b>6d</b> | 20 |
| IV.  | <sup>1</sup> H, <sup>13</sup> C and <sup>77</sup> Se NMR spectra of benzoselenazol-3(2H)-thiones <b>7a-7f</b>                     | 29 |
| V.   | References                                                                                                                        | 47 |


*N*-ethyl-*o*-iodobenzamide **4a**




*N*-ethyl-*o*-iodobenzamide **4a**




*N*-propyl-*o*-iodobenzamide **4b**




*N*-propyl-*o*-iodobenzamide **4b**




*N*-hexyl-*o*-iodobenzamide **4d**




*N*-hexyl-*o*-iodobenzamide **4d**




*N*-ethyl-*o*-iodobenzthioamide **5a**




*N*-ethyl-*o*-iodobenzthioamide **5a**




*N*-propyl-*o*-iodobenzthioamide **5b**




*N*-propyl-*o*-iodobenzthioamide **5b**




*N*-butyl-*o*-iodobenzthioamide **5c**




*N*-butyl-*o*-iodobenzthioamide **5c**




*N*-hexyl-*o*-iodobenzthioamide **5d**




*N*-hexyl-*o*-iodobenzthioamide **5d**




*N*-(3-methylbutyl)-*o*-iodobenzthioamide **5e**




*N*-(3-methylbutyl)-*o*-iodobenzthioamide **5e**




*N*-cyclohexyl-*o*-iodobenzthioamide **5f**




*N*-cyclohexyl-*o*-iodobenzthioamide **5f**




*N*-ethyl-1,2-benzisoselenazol-3(2*H*)-one **6a** [4]




*N*-ethyl-1,2-benzisoselenazol-3(2*H*)-one **6a** [4]




*N*-ethyl-1,2-benzisoselenazol-3(2*H*)-one **6a** [4]




*N*-propyl-1,2-benzisoselenazol-3(2*H*)-one **6b** [4]




*N*-propyl-1,2-benzisoselenazol-3(2*H*)-one **6b** [4]




*N*-propyl-1,2-benzisoselenazol-3(2*H*)-one **6b** [4]




*N*-hexyl-1,2-benzisoselenazol-3(2*H*)-one **6d** [5]




*N*-hexyl-1,2-benzisoselenazol-3(2*H*)-one **6d** [5]




*N*-hexyl-1,2-benzisoselenazol-3(2*H*)-one **6d** [5]




*N*-ethyl-1,2-benzisoselenazol-3(2*H*)-thione **7a** [6]




*N*-ethyl-1,2-benzisoselenazol-3(2*H*)-thione **7a** [6]




*N*-ethyl-1,2-benzisoselenazol-3(2*H*)-thione **7a** [6]




*N*-propyl-1,2-benzisoselenazol-3(2*H*)-thione **7b** [6]




*N*-propyl-1,2-benzisoselenazol-3(2*H*)-thione **7b** [6]




*N*-propyl-1,2-benzisoselenazol-3(2*H*)-thione **7b** [6]




*N*-butyl-1,2-benzisoselenazol-3(2*H*)-thione **7c** [6]




*N*-butyl-1,2-benzisoselenazol-3(2*H*)-thione **7c** [6]




*N*-butyl-1,2-benzisoselenazol-3(2*H*)-thione **7c** [6]




*N*-hexyl-1,2-benzisoselenazol-3(2*H*)-thione **7d**




*N*-hexyl-1,2-benzisoselenazol-3(2*H*)-thione **7d**




*N*-hexyl-1,2-benzisoselenazol-3(2*H*)-thione **7d**




*N*-(3-methylbutyl)-1,2-benzisoselenazol-3(2*H*)-thione **7e**




*N*-(3-methylbutyl)-1,2-benzisoselenazol-3(2*H*)-thione **7e**




*N*-(3-methylbutyl)-1,2-benzisoselenazol-3(2*H*)-thione **7e**




*N*-cyclohexyl-1,2-benzisoselenazol-3(2*H*)-thione **7f**



*N*-cyclohexyl-1,2-benzisoselenazol-3(2*H*)-thione **7f**



*N*-cyclohexyl-1,2-benzisoselenazol-3(2*H*)-thione **7f**



## References:

1. J. Blum, A. Fisher, E. Greener, *Tetrahedron*, The catalytic decomposition of secondary carboxamides by transition-metal complexes, **1973**, 29, 1073-1081.
2. B. Yao, Q. Wang, J. Zhu, *Angew. Chem. - International Edition*, Palladium(II)-Catalyzed Cyclizative Cross-Coupling of ortho-Alkynylanilines with ortho-Alkynylbenzamides under Aerobic Conditions, **2013**, 52, 12992-12996.
3. R. M. Baldwin, T. Lin, H.S. Winchell, Medi-Physics, Inc., Amides useful as brain imaging agents, **1981**, US Patent 4279887.
4. M. Pietka-Ottlik, H. Wojtowicz-Mlochowska, K. Kolodziejczyk, E. Piasecki, J. Mlochowski, *Chemical and Pharmaceutical Bulletin*, New organoselenium compounds active against pathogenic bacteria, fungi and viruses, **2008**, 56, 1423-1427.
5. A. Welter, C. Lambert, N. Dereu, A. Huther, E. Etschenberg, A. Nattermann and Cie GmbH, Benzisosenazolonyl derivatives and processes for the treatment of rheumatic disease, **1988**, US Patent 4774252.
6. A. Welter, S. Leyck, E. Etschenberg, A. Nattermann and Cie GmbH, Benzisosenazoletiones And Process For The Treatment Of Various Diseases In Humans, **1987**, US Patent 4711961.